The influence of smoking on the serum level of duloxetine

Pharmacopsychiatry

Volumn 41, Issue 4, 2008, Pages 151-155

  Fric, Mirijam ^a   Pfuhlmann, B ^b   Laux, G ^a   Riederer, P ^b   Distler, G ^a   Artmann, S ^a   Wohlschlager M ^a   Liebmann, M ^a   Deckert, J ^b  

^a Inn Salzach Hospital   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 1A2; DULOXETINE; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; OLANZAPINE; POLYCYCLIC HYDROCARBON; RISPERIDONE; TOBACCO SMOKE; VALPROIC ACID; ZIPRASIDONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL PATIENT; HUMAN; MALE; NATURALISTIC INQUIRY; PRIORITY JOURNAL; SMOKING; STEADY STATE;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYCYCLIC COMPOUNDS; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SMOKING; THIOPHENES;

EID: 49249116030     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1073173     Document Type: Article

References (33)

1. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50: 2974-2984
2. Bauer M, Whybrow PC, Angst J, Versiani M, Möller H-J. Biologische Behandlung unipolarer depressiver Störungen. Behandlungsleitlinien der World Federation of Societies of Biological Psychiatry (WFSBP). Wissenschaftliche Verlagsgesellschaft mbH Stuttgart 2004
3. Brosen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie 2004; 59: 5-12
4. Dalack GN, Glassman AH, Rivelli S, Covey L, Stetner F. Mood, major depression, and fluoxetine response in cigarette smokers. Am J Psychiatry 1995; 152: 398-403
5. DeLeon J, Becona E, Gurpegui M et al. The association between high nicotine dependence and severe mental illness may across countries. J Clin Psychiat 2002; 63: 812-816
6. Detke MJ, Lu Y, Goldstein DJ, Hayes JR et al. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. J Clin Psychiat 2002; 63: 308-315
7. Detke MJ, Lu Y, Goldstein DJ, MacNamara RK, Demitrack MA. Duloxetine 60mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002; 36: 383-390
8. Dunner DL, Goldstein DJ, Mallinckrodt C, Lu, Detke MJ. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety 2003; 18: 53-61
9. EMEA. European Public Assessment of Medical Products. Scientific discussion. Cymbalta 2005
10. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004; 76: 178-184
11. Faber MS, Jetters A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: Why, how and when? Bas Clin Pharmacol Toxicol 2005; 97: 125-134
12. George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkler J et al. Nicotine transdermal patch and atypical antipsychotic medication for smoking cessation in schizophrenia. Am J Psychiatry 2000; 157: 1835-1842
13. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demittrack MA. Duloxetine in the treatment of depression: a double- blind placebo-controlled comparison with paroxetine. J Clin Pharmacol 2004; 24: 389-399
14. Hiemke C, Hampel C, Weigmann H. Pharmakologie von Duloxetin. Eine therapeutische Option für verschiedene Indikationen. Psychopharmakotherapie 2006: 13: 12-18
15. Ishigooka J, Nagata E, Takahashi A et al. Simultaneous monitoring of inhibition of serotonin uptake by platelets and plasma drug concentrations following administration of duloxetine, a new antidepressant candidate, to healthy volunteers. Curr Ther Res 1997; 58: 679-692
16. Iyengar S, Bymaster FP, Wong DT, Ahmad L et al. Efficacy of the selective serotonin and norepinephrine reuptake inhibitor, duloxetine, in the formalin model of persistent pain. Eur Neuropsychopharmacol 2002; 12 (Suppl 13): 215
17. Lantz RJ, Hillespie TA, Rash TJ, Kuo F et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 2003; 31: 1142-1150
18. Lott RS, Baker DE. Duloxetine:a new antidepressant. Adv Pharmacy 2003; 1: 228-241
19. Millard R, Morre K, Rencken R, Yalcin I et al. Duloxetine versus placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int 2004; 93: 311-318
20. Müller WE, Haen E, Fritze J et al. Seleltive Serotonin- und Noradrenalin-Wiederaufnahmehemmer (SSNRI). Antidepressiva mit dualem Wirkungsmechanismus. Psychopharmakotherapie 2004; 11: 71-75
21. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressant and the cytochrome P450 system. Am J Psychiatry 1995; 153: 311-320
22. Salokanga RK, Saarijarvi S, Taiminen T et al. Effect of smoking on neuroleptics in schizophrenia. Schizophr Res 1997; 23: 55-60
23. Schreiber S, Backer MM, Pick CG. The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanism. Neurosci Lett 1999; 173: 85-88
24. Sharif ZA. Pharmacokinetics, metabolism, and drug drug interactions of atypical antipsychotics in special populations. Primary care companion J Clin Psychiat 2003; 64: 22-25
25. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000; 40: 161-167
26. Tang Y-I, Mao P, Li F-M, Chen Q Jiang F, Cai Z-J, Mitchell PB. Gender, age, smoking behaviour and plasma clozapine concentration in 193 Chinese inpatients with schizophrenia. Br J Clinical Pharmacol, Online Early Articles 12; Feb: 2007-03-05
27. Thor KB, Katofiasc AM. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neuron control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 1995; 274: 1014-1024
28. Kerreboreck P Van, Abrams P, Lange R, Slack M et al. Duloxetine vs. placebo in the treatment of European and Canadian women with stress urinary incontinence. Br J Obstet Gynaecol 2004; 111: 249-257
29. Zagermann-Muncke P. Rauchen gefahrdet ihre Arzneimitteltherapie. www.pharmazeutische-zeitung.de/fileadmin/pza/2004-29/pharma4. htm < http://www.pharmazeutische-zeitung.de/fileadmin/pza/2004-29/ pharma4.htm>
30. Ziedonis DM, Kasten TR, Glazer WM et al. Nicotine dependence and schizophrenia. Hosp and Comm Psychiat 1994; 45: 204-206
31. Ziedonis DM, George TP. Schizophrenia and nicotine use: report of pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 1997; 23: 247-254
32. Zink M, Knopf U, Mase E, Kuwilsky A, Deuschle M. Duloxetine treatment of major depressive episodes in the course of psychotic disorders. Pharmacopsychiatry 2006; 39: 109-111
33. Zullino DF, Delessert D, Eap CB, Preisig M, Baumann P. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine and olanzapine. Int Clin Psychopharmacol 2002; 17: 141-143